Skip to Content
Merck
CN

SML2916

AAL-R

≥98% (HPLC)

Synonym(s):

(R)-2-Amino-2-methyl-4-[4-(heptyloxy)phenyl]butan-1-ol, (R)-2-Amino-4-(4-(heptyloxy)phenyl)-2-methylbutan-1-ol, (R)-2-Amino-4-(4-heptyloxyphenyl)-2-methylbutanol, AAL(R)

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C18H31NO2
CAS Number:
241476-71-1
Molecular Weight:
293.44
UNSPSC Code:
41106300
NACRES:
NA.77

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

AAL-R, ≥98% (HPLC)

InChI

1S/C18H31NO2/c1-3-4-5-6-7-14-21-17-10-8-16(9-11-17)12-13-18(2,19)15-20/h8-11,20H,3-7,12-15,19H2,1-2H3/t18-/m1/s1

InChI key

ITJCKQTXCLGXHE-GOSISDBHSA-N

SMILES string

C[C@](N)(CO)CCC1=CC=C(C=C1)OCCCCCCC

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

Quality Level

100

Biochem/physiol Actions

More phosphorylatable FTY720 (fingolimod) analog with greater SphK2-dependent sphingosine 1-phosphate receptor (S1P) agonist efficacy in vitro and in vivo.
AAL-R [AAL(R)] is a FTY720 (fingolimod) analog and a much more rapidly activated sphingosine 1-phosphate receptor (S1P) agonist by sphingosine kinase 2 (SphK2)-mediated phosphorylation in vitro and in vivo. AAL-R triggers lymphocytes apoptosis in a SphK2-dependent manner (34%/84% remaining parental/SphK2-deficient Jurkat; 24 h 5 μM) with a significantly higher efficacy than its S-enantiomer AAL-S or FTY720 (%PI- mouse splenocytes = 27/ALL-R vs 56/FTY720 or ALL-S; 24 h 4 μM). AAL-R (0.1-0.3 mg/kg intratracheally), but not ALL-S, inhibits T-cell response to influenza infection and reduces pulmonary inflammation during Bordetella pertussis infection in mice (0.5 mg/kg intranasally).

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000221667
0000221667

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Peter Ettmayer et al.
Bioorganic & medicinal chemistry letters, 16(1), 84-87 (2005-10-21)
Fluorescently labeled chiral analogs of the immunomodulatory drug FTY720 and its corresponding phosphates with variable aliphatic spacers between the aromatic ring and the NBD label have been synthesized. Determining the influence of the spacer on the in vitro phosphorylation rate
Ciaran Skerry et al.
Infection and immunity, 87(2) (2018-12-05)
Incidence of whooping cough (pertussis), a bacterial infection of the respiratory tract caused by the bacterium Bordetella pertussis, has reached levels not seen since the 1950s. Antibiotics fail to improve the course of disease unless administered early in infection. Therefore
Jeremy Ardanuy et al.
Journal of immunology (Baltimore, Md. : 1950), 204(8), 2192-2202 (2020-03-11)
Type I and III IFNs play diverse roles in bacterial infections, being protective for some but deleterious for others. Using RNA-sequencing transcriptomics we investigated lung gene expression responses to Bordetella pertussis infection in adult mice, revealing that type I and
David R Gendron et al.
Frontiers in pharmacology, 8, 78-78 (2017-03-09)
In asthma, excessive bronchial narrowing associated with thickening of the airway smooth muscle (ASM) causes respiratory distress. Numerous pharmacological agents prevent experimental airway hyperresponsiveness (AHR) when delivered prophylactically. However, most fail to resolve this feature after disease is instated. Although
Ciaran Skerry et al.
The Journal of infectious diseases, 215(2), 278-286 (2016-11-07)
Recent data have demonstrated the potential of sphingosine 1-phosphate (S1P) receptor (S1PR) agonism in the treatment of infectious diseases. A previous study used a murine model of Bordetella pertussis infection to demonstrate that treatment with the S1PR agonist AAL-R reduces
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service